These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1804931)

  • 1. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1991 Nov; 35(3):192-7. PubMed ID: 1804931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of class and subclass antibody response to live and UV-inactivated RSV administered intranasally in mice.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1991 Nov; 35(3):198-205. PubMed ID: 1804932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.
    Tebbey PW; Scheuer CA; Peek JA; Zhu D; LaPierre NA; Green BA; Phillips ED; Ibraghimov AR; Eldridge JH; Hancock GE
    Vaccine; 2000 Jun; 18(24):2723-34. PubMed ID: 10781860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.
    Cano F; Plotnicky-Gilquin H; Nguyen TN; Liljeqvist S; Samuelson P; Bonnefoy J; Stâhl S; Robert A
    Vaccine; 2000 Jun; 18(24):2743-52. PubMed ID: 10781862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit.
    Oien NL; Brideau RJ; Walsh EE; Wathen MW
    Vaccine; 1994 Jun; 12(8):731-5. PubMed ID: 8091852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of breast feeding on the development of anti-idiotype antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization.
    Okamoto Y; Tsutsumi H; Kumar NS; Ogra PL
    J Immunol; 1989 Apr; 142(7):2507-12. PubMed ID: 2926142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice.
    Walsh EE
    Vaccine; 1993; 11(11):1135-8. PubMed ID: 8249433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine.
    Walsh EE
    J Infect Dis; 1994 Aug; 170(2):345-50. PubMed ID: 8035021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1990 Sep; 32(1):67-72. PubMed ID: 2243208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.
    Goetsch L; Plotnicky-Gilquin H; Aubry JP; De-Lys P; Haeuw JF; Bonnefoy JY; Nguyen NT; Corvaïa N; Velin D
    Vaccine; 2001 Jul; 19(28-29):4036-42. PubMed ID: 11427280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections.
    Wagner DK; Muelenaer P; Henderson FW; Snyder MH; Reimer CB; Walsh EE; Anderson LJ; Nelson DL; Murphy BR
    J Clin Microbiol; 1989 Mar; 27(3):589-92. PubMed ID: 2715331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
    Fisher RG; Crowe JE; Johnson TR; Tang YW; Graham BS
    J Infect Dis; 1999 Oct; 180(4):1324-7. PubMed ID: 10479165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.